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Background: We investigated whether a relationship between small airways dysfunction and bronchial
hyperresponsiveness (BHR), expressed both in terms of ease of airway narrowing and of excessive
bronchoconstriction, could be demonstrated in asthma.
Methods: 63 (36 F; mean age 42 yr ± 14) stable, mild-to-moderate asthmatic patients (FEV1 92% pred ±14; FEV1/FVC
75% ± 8) underwent the methacholine challenge test (MCT). The degree of BHR was expressed as PD20 (in μg) and as
ΔFVC%. Peripheral airway resistance was measured pre- and post-MCT by impulse oscillometry system (IOS) and
expressed as R5-R20 (in kPa sL−1).
Results: All patients showed BHR to methacholine (PD20 < 1600 μg) with a PD20 geometric (95% CI) mean value
of 181(132–249) μg and a ΔFVC% mean value of 13.6% ± 5.1, ranging 2.5 to 29.5%. 30 out of 63 patients had
R5-R20 > 0.03 kPa sL−1 (>upper normal limit) and showed ΔFVC%, but not PD20 values significantly different from the
33 patients who had R5-R20≤ 0.03 kPa sL−1 (15.8% ± 4.6 vs 11.5% ± 4.8, p < 0.01 and 156(96–254) μg vs 207 (134–322) μg,
p = 0.382). In addition, ΔFVC% values were significantly related to the corresponding pre- (r = 0.451, p < 0.001) and
post-MCT (r = 0.376, p < 0.01) R5-R20 values.
Conclusions: Our results show that in asthmatic patients, small airway dysfunction, as assessed by IOS, is strictly
associated to BHR, expressed as excessive bronchoconstriction, but not as ease of airway narrowing.
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Asthma is a chronic inflammatory disease affecting the
entire tracheo-bronchial tree, from the proximal airways
to the peripheral membranous bronchioles, the so-called
small airways. The dysfunction of small airways may
significantly influence the clinical manifestations and
functional aspects of asthma [1]. Small airway obstruc-
tion was associated with poor disease control [2,3] and
history of asthma exacerbations [3]. Importantly, small
airways obstruction seems to significantly contribute to
the degree of severity of bronchial hyperresponsiveness
(BHR) [4,5], which is a functional hallmark of asthma
[6], being a marker of worse disease outcome [7] and a
risk factor for asthma development [8]. Notably, low* Correspondence: chetta@unipr.it
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unless otherwise stated.values of the forced expiratory flow between 25% and
75% of vital capacity (FEF25–75) and of the forced expira-
tory flow at 50% of vital capacity (FEF50), considering
both as measures of small airway patency, were strictly
associated to BHR severity in children [4] and in adults
[5] with asthma, respectively. In these studies, BHR was
assessed as the provocative concentration [4] or dose [5]
of methacholine causing a 20% fall (PC20 or PD20) in
forced expiratory volume at 1st second (FEV1).
It is of note that BHR, expressed as a dose–response
curve to methacholine or histamine, may be character-
ized by two abnormalities consisting in a leftward shift
of the dose–response curve (ease of airway narrowing)
and in an upward displacement of the maximal response
(excessive bronchoconstriction) (Figure 1). The PD20
(or PC20), a single point in the dose–response curve, re-
flects exclusively the ease of airway narrowing. Although
both cross-sectional and longitudinal studies have showntd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Representative dose–response curves of three asthmatic
patients to inhaled methacholine with different slope (%/μg) and
PD20 (μg) values. Patient A (closed circles) 0.248%/μg and 72 μg;
patient B (open diamond) 0.112%/μg and 184 μg, patient C
(open circles) 0.037%/μg and 625 μg.
Alfieri et al. Respiratory Research 2014, 15:86 Page 2 of 8
http://respiratory-research.com/content/15/1/86a general relationship between PD20 (or PC20) values and
severity of asthma, the within subject relationship was
weaker [9]. On the other hand, the level of maximal re-
sponse to the bronchoconstrictor stimuli reflects the pro-
pensity for airway closure and is presumably the most
important physiopathological abnormality in asthma as
long as it may determine fatal risk. Interestingly, exces-
sive bronchoconstriction may be indirectly detected by
measuring the fall in lung volume during bronchoprovo-
cation testing.
Studies in humans [10] and in animal models [11,12]
have shown that changes in lung volume and in paren-
chymal elastic load are related to the bronchoconstrictor
response to methacholine. Notably, the maximal re-
sponse of lung resistance to inhaled methacholine in-
creases with decreasing lung volume and elastic recoil
pressure [10-12]. Lung volume changes act by altering
the forces of interdependence between airways and par-
enchyma that oppose airway smooth muscle contraction.
Based on these findings, Gibbons et al. [13] proposed an
indirect method for detection of excessive bronchocon-
striction in patients with asthma by measuring the per-
centage fall in forced vital capacity (FVC) at PC20
(ΔFVC%) during bronchoprovocation testing. This index
of airway closure was not related to the PC20 and was as
reproducible as PC20 over a long period [13]. Further-
more, ΔFVC% correlated to asthma treatment in adult
patients [13,14] and to the presence of symptoms in
children with asthma [15].
The functional assessment of small airways is a chal-
lenging matter, given that the distal lung is relatively in-
accessible for measurements. The ability of spirometry
parameters to discriminate small airway obstruction is
still debated [16]. On the other hand, the forced oscillationtechnique has been successfully used as a measure of the
airway resistance heterogeneity and gas trapping, giving
comparable results to the multiple breath nitrogen wash-
out [17]. Furthermore, the impulse oscillometry system
(IOS) has been increasingly used to measure both proximal
and peripheral airway resistance in adults [2,3] and chil-
dren [18,19] with asthma. The main advantage of this
simple, noninvasive and sensitive technique [20] is that it
does not require forced maneuvers, which may affect bron-
chial tone.
The aim of the present study was to ascertain whether
a relationship between small airways dysfunction and se-
verity of BHR may be demonstrated in patients with
mild-to-moderate asthma. Small airway obstruction was
assessed by means of IOS and BHR to methacholine was
expressed both in terms of PD20, as a measure of ease of
airway narrowing, and in terms of ΔFVC%, as a measure
of excessive bronchoconstriction.
Methods
Subjects and study design
Adult patients (16 years of age and older, BMI ≤ 30 kg/m2)
with asthma diagnosis according to the international
guidelines [21], including current smokers, were eligible to
take part in the study and were consecutively recruited
from our Asthma Outpatient Clinic.
Between 9 and 12 a.m. on the same day, all patients
underwent routine clinical history and physical examin-
ation. For each patient, BMI (kg/m2), atopy and asthma
therapy were recorded. Asthma control was assessed
using the Italian version of the Asthma Control Test
[22]. Subsequently as part of their visit, patients under-
went IOS before and after methacholine challenge test-
ing (MCT). Patients were advised to omit inhaled
bronchodilators 24 h before IOS and MCT.
The study was performed in accordance with the
Good Clinical Practice guidelines recommended by the
International Conference on Harmonization of Technical
Requirements. The study was approved by the Ethics
Committee for the Province of Parma (Italy) and all pa-
tients gave their informed consent.
Impulse oscillometry
Impulse oscillometry was performed using the Jaeger
MasterScreen-IOS (Carefusion Technologies, San Diego,
CA, USA), following standard recommendations [20]. In
short, patients were asked to wear a nose-clip and were
seated during tidal breathing with their neck slightly ex-
tended and their lips sealed tightly around the mouthpiece,
and while firmly supporting their cheeks with their hands.
A minimum of three trials, each lasting 30 s, were per-
formed and mean values were taken for each value.
Respiratory resistance at 5 and 20 Hz (R5 and R20, in
kPa s l−1) were used as indices of total and proximal
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from 5 to 20 Hz (R5-R20, in kPa s l−1) was considered as
an index for the resistance of peripheral airways. More-
over, reactance at 5 Hz (X5, in kPa s l−1) was considered
as a representative marker of peripheral airway abnor-
malities. Data are presented as raw data. An upper limit
of normal for R5-R20 was chosen at 0.030 kPa s l−1, as
previously reported [23]. Data obtained in our laboratory
in 41 asymptomatic non-smoking subjects (24 F; age
range 24–60 years; BMI range 18.0-29.7 kg/m2) without
a history of lung disease and in whom spirometry results
were within normal limits fell below these upper limits
of normal. Our R5-R20 laboratory data were normally dis-
tributed with a mean ± SD value of 0.021 ± 0.029 kPa s l-1
(95% CI: 0.011-0.030 kPa s l−1).
Lung function testing and methacholine challenge testing
Lung function was measured by a flow-sensing spirom-
eter connected to a computer for data analysis (CPFS/D
Spirometer, MedGraphics, St Paul, MN, USA) meeting
the American Thoracic Society (ATS) standards. FVC,
FEV1 and FEF25–75 were recorded and expressed as per-
cent of predicted value. FEV1/FVC was also recorded and
expressed as ratio.
Methacholine challenge testing was performed according
to a standardized procedure. Each participant inhaled
doubling increasing dose of methacholine (20–2400 μg),
vaporized by a dosimeter with a driving pressure of
180 kPa generating an output of 10 μL/puff with particle
size within the respirable range (<5 μM) (Dosimeter
MB3; Mefar, Brescia, Italy). Patients underwent spirom-
etry before and after each inhalation in order to record
FEV1, FVC and FEF25–75. The test was stopped when ei-
ther FEV1 fell by 20% or more from baseline measured
after saline inhalation or 2400 μg methacholine cumula-
tive dose was reached. PD20 in μg was calculated by linear
interpolation of the dose–response curve and the values
were log-transformed before analysis. A dose–response
slope to methacholine (DRS,%/μg) was also calculated by
least-squares linear regression analysis. The percentage
fall in FVC (ΔFVC%) at the PD20 relative to the baseline
FVC after saline inhalation was also calculated using log-
linear interpolation [13].
Statistical analysis
The distribution of variables was assessed by means of
Kolmogorov-Smirnov Goodness-of-Fit test. Variables are
expressed as mean ± SD, unless otherwise specified. Un-
paired and paired t-test, Mann Whitney test and Pearson
χ2 test were used for comparisons, when appropriate. To
examine relationships between measures Pearson’s cor-
relation coefficient (r) and Spearman rank order correl-
ation coefficient (rs) were used, when appropriate. The
receiver operating characteristic (ROC) curve method[24] was used to plot the true positive rate (sensitivity)
in function of the false positive rate (100-specificity), for
different cut-off points of ΔFVC% with respect to R5-
R20 > 0.030 kPa s l−1, as threshold value. A p value ≤ 0.05
was considered as significant.
Results
We consecutively enrolled 71 patients (43 F, age range 16–
74 yr) with asthma severity ranging from mild to severe.
Eight patients were excluded due to a BMI ≥ 30 kg/m2.
The 63 included patients showed FEV1 and FEV1/FVC
values ranging respectively from 65 to 132% of predicted
value and from 58 to 96%. Twenty-one out of 63 asthmatic
patients were on ICS (500–1000 mcg/day of beclometha-
sone dipropionate or equivalent) plus long acting beta2-
agonists, 9 patients were on ICS alone (500 mcg/day of
beclomethasone dipropionate or equivalent) and the
remaining 33 patients controlled their symptoms with in-
haled salbutamol prn. Fifty-two patients were atopics
(82%). Forty-nine out of 63 patients (78%) had well con-
trolled asthma (ACT > 20). In all patients, the ACT me-
dian score was 24, ranging from 13 to 25.
All patients showed BHR to MCT (PD20 < 1600 mcg)
with a PD20 geometric (95% CI) mean value of 181
(132–249) μg, a DRS geometric (95% CI) mean value of
0.103 (0.074-0.143)%/μg and with a ΔFVC% mean and
median value of 13.5% ± 5 and 14.0% respectively, ran-
ging from 2.5 to 29.5% (Table 1). In all patients, there
was no relationship between ΔFVC% and PD20 (r = −0.132;
p = 0.303) (Figure 2). In contrast ΔFVC% and DRS
values were weakly but significantly and positively related
(r = 0.260; p = 0.039) (Figure 3). A significant difference was
found in ΔFVC (16.1% ± 5.8 vs 12.8% ± 4.7; p = 0.037), but
not in PD20 values [143(84–243) μg vs 200(132–286) μg;
p = 0.431], when patients were subdivided in poorly con-
trolled (ACT ≤ 19) and in well controlled (ACT > 19)
(Figure 4). Pre- and post-MCT R5-R20 values were 0.057
kPa s l−1 ± 0.072 and 0.184 kPa s l−1 ± 0.148 (p < 0.001).
When patients were categorized by R5-R20 upper
limit of normality [23], 30 out of 63 patients had R5-
R20 > 0.030 kPa s l−1. The two groups of patients sig-
nificantly differed in ΔFVC% value (p < 0.01), but not
in PD20, in DRS and in spirometry values (Table 1).
In addition, twenty-one out of 30 patients with R5-
R20 > 0.030 kPa s l−1 and 10 out 33 patients with R5-
R20 ≤ 0.030 kPa s l−1 had a ΔFVC% value higher than
the median value of ΔFVC% of the entire group of pa-
tients (χ2 = 7.222, p = 0.007) (Figure 2). As compared
to patients with ≤ 0.030 kPa s l−1, patients with R5-
R20 > 0.030 kPa s l−1 were significantly older and also
differed in gender, the vast majority being women. The
ratio between the number of atopic and that of non
atopic individuals and the ratio between the number of
patients with well controlled asthma (ACT > 19) and that
Table 1 Characteristics of patients with asthma
All patients (No. 63) Patients with R5-R20
≤ 0.03 kPa s l−1 (No. 33)
Patients with R5-R20
> 0.03 kPa s l−1 (No. 30)
Age (years) 42 ± 14 38 ± 12 45 ± 15*
Sex (F/M) 36/27 13/20 23/7**
BMI (kg/m2) 24 ± 3 23 ± 2 25 ± 3
Atopy (Y/N) 52/11 31/2 21/9*
Smoking (Y/N) 12/51 9/24 4/26
ICS use (Y/N) 29/34 14/19 15/15
ICS dose (μg/day)# 701 ± 540 779 ± 598 628 ± 490
ACT > 20/ACT≤ 19 49/14 29/4 20/10*
FEV1 (% of pred) 92 ± 14 94 ± 13 90 ± 15
FVC (% of pred) 99 ± 13 102 ± 12 97 ± 13
FEV1/SVC (%) 75 ± 8 75 ± 6 75 ± 9
FEF25–75 (% pred) 76 ± 25 77 ± 21 74 ± 29
R5-R20 (kPa s l−1) 0.057 ± 0.072 0.011 ± 0.014 0.108 ± 0.076**
X5 (kPa s l-1) −0.134 ± 0.07 −0.098 ± 0.02 −0.172 ± 0.09**
PD20 (μg) 181 (132–249) 207 (134–322) 156 (96–254)
DRS (%/μg) 0.103 (0.074-0.143) 0.086 (0.054-0.135) 0.125 (0.076-0.205)
ΔFVC% 13.6 ± 5.1 11.5 ± 4.8 15.8 ± 4.6**
Values are expressed as mean ± SD, ratio or geometric mean (Confidence Intervals).
#only in patients using ICS; *p < 0.05; **p < 0.01.
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were significantly lower in patients with R5-R20 > 0.030
kPa s l−1, as compared to the patients with R5-R20 ≤ 0.030
kPa s l1 (2.3 vs 15.5; χ2 = 6.249, p = 0.012 and 2.0 vs 7.25;
χ2 = 4.091, p = 0.043, respectively).
In all patients, ΔFVC% values were significantly related
to the corresponding pre- (r = 0.451, p < 0.001) and
post-MCT (r = 0.376, p < 0.01) R5-R20 (Figure 5) and





R5-R20 > 0.03kPa s l -1







Figure 2 Relationship between ΔFVC% and PD20 methacholine
in 63 asthmatic patients with R5-R20≤ 0.03 kPa s l−1 (open circles)
and with R5-R20 > 0.03 kPa s l−1 (closed circles). The interrupted
line represents the median value of ΔFVC%, corresponding to 14%.
Twenty-one out of 30 patients with R5-R20 > 0.030 kPa s l−1 and 10
out 33 patients with R5-R20≤ 0.030 kPa s l−1 had a ΔFVC% value
higher than the median value of ΔFVC% of the entire group of
patients (χ2 = 7.222, p = 0.007).p < 0.001) X5 (Figure 6) values, but not to the correspond-
ing pre- (r = − 0.220, p = 0.082) and post-MCT (r = −0.117,
p = 0.386) FEF25–75 values. In addition, according to the
ROC curve method, the plot of the true positive rate in
function of the false positive rate for different cut-off points
of ΔFVC% with respect to R5-R20 > 0.03 kPa s l-1, as
threshold value, showed a 0.758 (p < 0.01) area under
curve value. The ΔFVC% cut-off point, which maxi-
mized sensitivity and specificity, was ≥ 14.5% (0.67 sensi-












Figure 3 Relationship between ΔFVC% and DRS in 63
asthmatic patients.




























Figure 4 Mean, standard deviation and range values of ΔFVC%
(upper panel) and PD20 methacholine (lower panel) in 49 well
controlled and 14 poorly controlled asthmatic patients.



















































Figure 5 Relationship between ΔFVC% and R5-R20 pre-MCT
(upper panel) and R5-R20 post-MCT (lower panel) in 63
asthmatic patients.
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The main finding of this study is that a strict relation-
ship between small airway dysfunction, as assessed by
IOS, and bronchial hyperresponsiveness to methacholine
is present in patients with mild to moderate asthma.
The bronchial hyperresponsiveness can be demonstrated
as ease of airway narrowing and as excessive broncho-
constriction expressed as PD20 and ΔFVC%, respectively.
In the present study, those patients with increased per-
ipheral airway resistance experienced a significantly higher
ΔFVC% during the methacholine challenge than patients
with normal peripheral airway resistance by showing, on
the contrary, similar PD20 values. In addition, patients
with small airway dysfunction were older, largely female
and with a lower percentage of atopic and well-controlled
individuals, as compared to the remaining ones.
Methacholine challenge testing is being used to assess
hyperresponsiveness of the entire bronchial tree both in
the clinical and research setting. However, whether de-
position and effect of inhaled particles of the broncho-
constrictor agent may occur even in the small airways is
still open to debate, by relying on different factors, suchas inhalation manoeuver and particle size, which is in
turn mainly determined by the nebulizer output. In
patients with asthma, Cohen et al. [25] investigated
whether small and large particle sizes of aerosolized
adenosine monophosphate (AMP) lead to similar severity
of airway hyperresponsiveness. They found that large-
particle (9.9 μM) PC20 values were smaller than those of
standard particles (3.7 μM), which in turn were smaller
than small-particle (1.06 μM) PC20 values. These findings
imply that the airway hyperresponsiveness degree is
dependent on the particle size of the inhaled broncocon-
strictor agent and, in this case, that small airways also do
not show a similar severity of hyperresponsiveness com-
pared to large airways. In our study, we used the MB3
Mefar Dosimeter, a largely used dosimeter, which at the
recommended driving pressure of 180 kPa can assure an
output with particle size within the respirable range
(<5 μM) [26]. Accordingly, we may assume that in our
asthmatic patients the aerosolized methacholine reached
the lower airways by acting in this part of the tracheo-
bronchial tree.
While a PD20 value is measurable in the vast majority
of asthma patients during the methacholine challenge, a
















































Figure 6 Relationship between ΔFVC% and X5 pre-MCT (upper
panel) and X5 post-MCT (lower panel) in 63 asthmatic patients.
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matic patients. In the present study, the ΔFVC values
ranged from 2.5 to 29.5% with a mean value of 13.6% ± 5.1
and a normal frequency distribution. Our findings are very
similar to those by Gibbons et al. [13] and Abisheganaden
et al. [14], who previously reported a mean ΔFVC% of
13.2% ± 5.5 and 13.8% ± 4.8, respectively. Moreover, in line
with these previous studies [13,14], we also found no rela-
tionship between ΔFVC% and PD20 values. Patients with
the same value of PD20 may show different falls in FVC
during methacholine challenge (Figure 2). Taken together,
Gibbons et al. [13] Abisheganaden et al. [14] as well as our
findings suggest that bronchial hyperresponsiveness in vivo
is a composite functional disorder and that the mecha-
nisms underlying excessive bronchoconstriction and ease
of airway narrowing during the methacholine challenge are
different. In our study, we also found that the ΔFVC% was
significantly higher in patients with poorly controlled dis-
ease, as compared to well-controlled patients. These results
are consistent with the findings of previous studies [13-15]
that related ΔFVC% to the severity of asthma and consid-
ered it as a useful index in detecting the patients at risk for
serious disease.In the present study, we provide the first evidence that
in asthmatic patients excessive bronchoconstriction
expressed by ΔFVC% is strictly associated to small air-
way dysfunction, as assessed by IOS. As compared to
patients with R5-R20 ≤ 0.030 kPa s l−1, patients with R5-
R20 > 0.030 kPa s l−1 had a high likelihood to be associated
to a ΔFVC% greater than 14.5% during a methacholine-
induced bronchoconstriction. Moreover, in all patients we
found a significant relationship between the baseline values
both of the peripheral airway resistance and reactance,
expressed respectively by R5-R20 and X5, and ΔFVC%.
Three mechanical factors are called upon to explain the
excessive airway narrowing in asthma: an increased con-
tractility of airway smooth muscle induced by humoral me-
diators or abnormalities in neural control; a lack of a
normal inhibiting factor which can prevent further short-
ening when the smooth muscle begins to shorten, so that
the muscle never develops maximum force and degree of
shortening; a decrease in elastic load, provided by cartilage
and the surrounding parenchyma, so that it is easier to
narrow an asthmatic bronchus as compared to a normal
bronchus [27]. It is conceivable that the three above mech-
anisms may be amplified in the peripheral membranous
bronchioles, which are without cartilage and, in asthmatic
patients, may be the site of intense and extensive pro-
cesses of inflammation [28-30] and remodeling [31,32].
Thus, inflammatory and structural changes may result in
destabilization of these airways, which may become in turn
prone to excessive bronchoconstriction. When directly
measured in vivo, the small airway reactivity to histamine
was significantly enhanced in asthmatic patients relative to
normal controls with Isoproterenol being able to com-
pletely reverse the increase in peripheral airway resistance
in the latter, but not in the former [33].
In line with previous studies, which showed a relation-
ship between small airway dysfunction, as assessed by
IOS, and uncontrolled disease, both in adults [2,3] and
in children [34,35] with asthma, our group of patients
with increased values of peripheral airway resistance had
a greater proportion of poorly controlled asthma. Inter-
estingly, these patients did not differ from patients with
normal values of peripheral airway resistance in terms of
FEV1 and FEV1/SVC. This is not surprising since patients
with severe asthma may show similar airflow obstruction,
but significantly increased air trapping, as compared to pa-
tients with non severe asthma [36]. Moreover, in our study
patients with increased values of peripheral airway resist-
ance were older, largely female and with a lower percentage
of atopic individuals, as compared to the patients with nor-
mal values of peripheral airway resistance. Whether, age
gender or atopy may directly affect the extent of small air-
way involvement in asthma has up to now not been deeply
investigated. In a small group of asthmatic patients, males
and females showed different small airways impairment
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ment by attenuated small airway patency and females by
small airway inflammation [37]. Air trapping, older age, fe-
male gender and less atopy were also significantly associ-
ated to the severe asthma phenotype [38].
Conclusion
The present study shows that mild-to-moderate asth-
matic patients with small airway dysfunction, as assessed
by IOS, have excessive bronchoconstriction during the
methacholine challenge, which is an important index
of disease severity. Though association does not imply
causality, the results of our study suggest a significant
contribution of small airways in the pathophysiology of
bronchial hyperresponsiveness. This fact may have im-
plications for the treatment of asthmatic patients by in-
creasing in importance the small-particle aerosols.
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